BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 32123532)

  • 1. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.
    Ding H; Zhang X; Su Y; Jia C; Dai C
    Cell Mol Biol Lett; 2020; 25():8. PubMed ID: 32123532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
    Ding H; Liu J; Zou R; Cheng P; Su Y
    J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.
    Nault JC; Fabre M; Couchy G; Pilati C; Jeannot E; Tran Van Nhieu J; Saint-Paul MC; De Muret A; Redon MJ; Buffet C; Salenave S; Balabaud C; Prevot S; Labrune P; Bioulac-Sage P; Scoazec JY; Chanson P; Zucman-Rossi J
    J Hepatol; 2012 Jan; 56(1):184-91. PubMed ID: 21835143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP).
    Tang C; Feng W; Bao Y; Du H
    Bioengineered; 2021 Dec; 12(1):2119-2131. PubMed ID: 34057016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCAPG2 overexpression promotes hepatocellular carcinoma proliferation and metastasis through activating the STAT3 and NF-κB/miR-188-3p pathways.
    Meng F; Zhang S; Song R; Liu Y; Wang J; Liang Y; Wang J; Han J; Song X; Lu Z; Yang G; Pan S; Li X; Liu Y; Zhou F; Wang Y; Cui Y; Zhang B; Ma K; Zhang C; Sun Y; Xin M; Liu L
    EBioMedicine; 2019 Jun; 44():237-249. PubMed ID: 31176678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ANP32A promotes the proliferation, migration and invasion of hepatocellular carcinoma by modulating the HMGA1/STAT3 pathway.
    Tian Z; Liu Z; Fang X; Cao K; Zhang B; Wu R; Wen X; Wen Q; Shi H; Wang R
    Carcinogenesis; 2021 Apr; 42(3):493-506. PubMed ID: 33332531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual functions of STAT3 in LPS-induced angiogenesis of hepatocellular carcinoma.
    Wang Z; Yan M; Li J; Long J; Li Y; Zhang H
    Biochim Biophys Acta Mol Cell Res; 2019 Apr; 1866(4):566-574. PubMed ID: 30521872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINC00346 promotes hepatocellular carcinoma progression via activating the JAK-STAT3 signaling pathway.
    Yin YZ; Zheng WH; Zhang X; Chen YH; Tuo YH
    J Cell Biochem; 2020 Jan; 121(1):735-742. PubMed ID: 31478228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
    Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
    World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway.
    Li Y; Liu G; Li X; Dong H; Xiao W; Lu S
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2826-2832. PubMed ID: 30115383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice.
    Huang W; Chen Z; Zhang L; Tian D; Wang D; Fan D; Wu K; Xia L
    Gastroenterology; 2015 Oct; 149(4):1053-67.e14. PubMed ID: 26065367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated expression of GNAS promotes breast cancer cell proliferation and migration via the PI3K/AKT/Snail1/E-cadherin axis.
    Jin X; Zhu L; Cui Z; Tang J; Xie M; Ren G
    Clin Transl Oncol; 2019 Sep; 21(9):1207-1219. PubMed ID: 30767161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD63 negatively regulates hepatocellular carcinoma development through suppression of inflammatory cytokine-induced STAT3 activation.
    Yu S; Chen J; Quan M; Li L; Li Y; Gao Y
    J Cell Mol Med; 2021 Jan; 25(2):1024-1034. PubMed ID: 33277798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
    Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
    Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA GNAS-AS1 knockdown inhibits keloid cells growth by mediating the miR-188-5p/RUNX2 axis.
    Liu Y; Li L; Wang JY; Gao F; Lin X; Lin SS; Qiu ZY; Liang ZH
    Mol Cell Biochem; 2023 Apr; 478(4):707-719. PubMed ID: 36036334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.